Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,236Revenue (TTM) $M366Net Margin (%)-32.6Altman Z-Score18.2
Enterprise Value $M5,627EPS (TTM) $-0.9Operating Margin %-32.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score1.5Pre-tax Margin (%)-32.6Higher ROA y-yN
Price/Book9.110-y EBITDA Growth Rate %-3.7Quick Ratio5.5Cash flow > EarningsN
Price/Sales15.95-y EBITDA Growth Rate %-3.6Current Ratio6.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-24.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M140ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENVanguard Health Care Fund 2015-12-31 Sold Out -0.01%$37.16 - $45.52
($41.72)
$ 44.497%Sold Out0
SGENVanguard Health Care Fund 2015-06-30 Buy 0.02%$34.03 - $49.63
($41.17)
$ 44.498%New holding170,125
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.85)
$ 44.49310%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 44.49359%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 44.49281%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.11)
$ 44.49388%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 44.49373%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2016-07-06Sell7,618$40.568.46view
SIEGALL CLAY BPresident and CEO 2016-06-06Sell22,083$43.590.92view
Cline Darren SEVP, Commercial 2016-06-02Sell3,366$42.074.56view
SIEGALL CLAY BPresident and CEO 2016-05-27Sell48,660$40.418.86view
SIEGALL CLAY BPresident and CEO 2016-05-24Sell8,400$40.099.73view
SIEGALL CLAY BPresident and CEO 2016-05-17Sell7,618$35.1625.11view
SIEGALL CLAY BPresident and CEO 2016-04-25Sell800$409.97view
SIEGALL CLAY BPresident and CEO 2016-04-05Sell7,618$36.1221.79view
SIEGALL CLAY BPresident and CEO 2016-03-22Sell15,236$35.5223.85view
BAKER FELIXDirector, 10% Owner 2016-03-17Buy124,065$31.8538.12view

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 

More From Other Websites
Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin)... Jul 18 2016
Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin)... Jul 18 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers Jul 15 2016
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial... Jul 13 2016
Seattle Genetics/Takeda Adectris' Label Expanded in the EU Jul 07 2016
Seattle Genetics drug gets OK for additional cancer therapies in Europe Jul 06 2016
Seattle Genetics Announces European Commission Approval of ADCETRIS® (Brentuximab Vedotin) as... Jul 06 2016
5 Best-Positioned Biotech Stocks on Brexit Volatility Jun 28 2016
Seattle-area stocks: Brexit news punishes Tableau, Juno, Paccar in Friday trading Jun 24 2016
Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : June 21, 2016 Jun 21 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : June 20,... Jun 20 2016
Agios Upgraded As Anemia Drug Data Soothes Safety Concerns Jun 13 2016
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML)... Jun 11 2016
IBB Holdings: How Are Their Moving Averages Trending? Jun 09 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)